Supplementary Table 1: Perianal disease previous surgeries in the 207 patients treated with ustekinumab.

|  |  |
| --- | --- |
| **Types of prior perianal surgery\*** |  |
| Seton drainage | 162 |
| Abscess drainage | 123 |
| Fistulotomy / Fistulectomy | 13 |
| Rectal advancement flap | 6 |
| Fibrin glue  Fistula plug | 23  6 |
|
| Stricture dilatation | 13 |
| Fecal diversion | 28 |
| Others\*\* | 8 |

***\**** combined types possible

\*\* expanded adipose-derived stem cells (n=6), ligation of the intersphincteric fistula tract (n=1), fissurectomy (n=1)

Supplementary Table 2: Characteristics of perianal Crohn’s disease treatments in the 148 patients with active perianal disease at the initiation of ustekinumab.

|  |  |
| --- | --- |
| **Active perianal disease at initiation** | **n= 148** |
| Types of perianal disease\* | Primary 33, Secondary 129, Tertiary 25 |
| Draining abscess last 3 months before treatment, n (%) | 27 (18) |
| Draining seton last 3 months before treatment, n (%) | 57 (39) |
| Medical therapy for perianal disease last 3 months before treatment, n (%) | Antibiotics 69 (46.6), Topics 6 (4) |
| **Surgical therapy for perianal lesions under ustekinumab treatment\* n (%)** | **43 (29)** |
| Suppuration drainage, n (%) | Seton drainage 20 (13.5), Abscess drainage 17 (11.5) |
| Fistulotomy / Fistulectomy, n (%) | 6 (4) |
| Advancement flap, n (%) | Rectal flap 1 (0.7), Muscle flap 1 (0.7) |
| Fibrin glue, n (%) | 11 (7.4) |
| Fistula plug, n (%) | 2 (1.3) |
| Stricture dilatation, n (%) | 4 (2.7) |
| Fecal diversion, n (%) | 5 (3.4) |
| Abdominoperineal resection  Intestinal continuity restoration | 0 (0)  3 (2) |

***\**** combined types possible

 Supplementary Figure 1: Kaplan-Meier curve of treatment cessation-free survival in the 148 patients with active perianal disease at the initiation of ustekinumab.



Supplementary Figure 2: Kaplan-Meier curve of recurrence-free survival in the 59 patients with inactive perianal disease at the initiation of ustekinumab.